Program
Denosumab
Also written as “denosumab”, “CT-P41” and “AMG 162”.
Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Breast Neoplasms · Giant Cell Tumor of Bone · Prostatic Neoplasms, led by 13 companies.
Drug pageDenosumab: every studyMany companies study it; this page follows only the 78 they lead. All 207 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 553 open or running | phase 4since Nov 20, 2012 | Aug 6, 2002 | Jan 23, 2027phase 4 · NCT06332014 |
| GlaxoSmithKlineits history only | 50 open or running | phase 3since Oct 20, 2011 | Oct 20, 2011 | none ahead |
| Celltrionits history only | 30 open or running | phase 3since Feb 12, 2021 | Aug 11, 2020 | none ahead |
| Mabwell (Shanghai) Bioscienceits history only | 30 open or running | phase 3since Jan 18, 2022 | Mar 12, 2021 | none ahead |
| Daiichi Sankyoits history only | 20 open or running | phase 3since May 16, 2008 | May 16, 2008 | none ahead |
| Fosun Pharmaits history only | 20 open or running | phase 3since Apr 23, 2022 | Aug 27, 2020 | none ahead |
| Shanghai Biomabs Pharmaceuticalits history only | 20 open or running | phase 3since Oct 15, 2020 | Apr 18, 2019 | none ahead |
| AryoGen Pharmedits history only | 10 open or running | phase 3since Sep 19, 2017 | Sep 19, 2017 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Jan 22, 2017 | Jan 22, 2017 | none ahead |
| Lambda Therapeutic Researchits history only | 11 open or running | phase 3since Jun 7, 2022 | Jun 7, 2022 | none ahead |
| Luye Pharma Groupits history only | 11 open or running | phase 3since May 2, 2023 | May 2, 2023 | none ahead |
| Samsung Bioepisits history only | 10 open or running | phase 1since Nov 3, 2020 | Nov 3, 2020 | none ahead |
| Taizhou Mabtech Pharmaceuticalits history only | 10 open or running | phase 1since Apr 7, 2024 | Apr 7, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since Aug 6, 2002.
- May 31, 2013Phase 1 study in Healthy VolunteerNCT01869686 · 12 enrolled · United States
- Sep 24, 2013Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01951586 · 226 enrolled · United States, Australia, Canada and more
- Jan 31, 2014Phase 1 study in Healthy VolunteerNCT02053753 · 146 enrolled · United States
- Feb 25, 2014Phase 1 study in Healthy Volunteer, Female, BreastNCT02099461 · 82 enrolled · United States
- Mar 12, 2014Phase 4 study in Bone DiseasesNCT02101164
- Jun 4, 2014Phase 3 study in Osteoporosis, PostmenopausalNCT02157948 · 394 enrolled · United States, Canada, Denmark and more
- Jan 28, 2015Phase 3 study in Osteogenesis ImperfectaNCT02352753 · 153 enrolled · United States, Australia, Belgium and more
- May 8, 2017Phase 3 study in OsteoporosisNCT03164928 · 24 enrolled · United States, Australia, Belgium and more
- Sep 29, 2017Phase 4 study in Giant Cell Tumor of BoneNCT03301857 · 85 enrolled · United States, Australia, France and more
- Jun 21, 2018Phase 3 study in Osteogenesis ImperfectaNCT03638128 · 75 enrolled · United States, Australia, Belgium and more
- Jan 28, 2019Phase 1 study in OsteoporosisNCT03822078 · 45 enrolled
- Oct 7, 2020Phase 4 study in Giant Cell Tumor of BoneNCT04586660 · 36 enrolled · China, Taiwan
- Mar 19, 2024Phase 4 study in OsteoporosisNCT06332014 · 102 enrolled · China
- Sep 5, 2024Phase 4 study in Glucocorticoid-induced OsteoporosisNCT06588153 · 102 enrolled · China
Ahead
- Jan 23, 2027Primary completion: phase 4 study in OsteoporosisNCT06332014
- Apr 27, 2027Primary completion: phase 4 study in Glucocorticoid-induced OsteoporosisNCT06588153
- Mar 7, 2028Primary completion: phase 4 study in Giant Cell Tumor of BoneNCT04586660
TargetBeta
“A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity”NCIt, by rule
“Tumor necrosis factor ligand superfamily member 11 inhibitor”ChEMBL 37, by rule
Other programs on TNFSF11
Studies
All 55 Amgen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06588153Glucocorticoid-induced Osteoporosis · China | 4 | Active, not recruiting | Apr 27, 2027 | 102 |
| NCT06332014Osteoporosis · China | 4 | Active, not recruiting | Jan 23, 2027 | 102 |
| NCT04586660Giant Cell Tumor of Bone · China, Taiwan | 4 | Active, not recruiting | Mar 7, 2028 | 36 |
| NCT03822078Osteoporosis | 1 | Completed | Dec 24, 2004 | 45 |
| NCT03638128Osteogenesis Imperfecta · United States, Australia, Belgium and more | 3 | Terminated | Mar 28, 2022 | 75 |
| NCT03301857Giant Cell Tumor of Bone · United States, Australia, France and more | 4 | Completed | Jul 27, 2023 | 85 |
| NCT03164928Osteoporosis · United States, Australia, Belgium and more | 3 | Completed | Dec 13, 2021 | 24 |
| NCT02352753Osteogenesis Imperfecta · United States, Australia, Belgium and more | 3 | Terminated | Mar 26, 2022 | 153 |
| NCT02157948Osteoporosis, Postmenopausal · United States, Canada, Denmark and more | 3 | Completed | Jul 2015 | 394 |
| NCT02101164Bone Diseases | 4 | Withdrawn | Nov 2014 | 0 |
| NCT02099461Healthy Volunteer, Female, Breast · United States | 1 | Completed | Jul 2014 | 82 |
| NCT02053753Healthy Volunteer · United States | 1 | Completed | Aug 2014 | 146 |
| NCT01951586Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Jul 29, 2016 | 226 |
| NCT01869686Healthy Volunteer · United States | 1 | Completed | Sep 2013 | 12 |
| NCT01824342Castrate-resistant Prostate Cancer · Czech Republic, United Kingdom | 3 | Completed | Feb 2014 | 18 |
| NCT01732770Osteoporosis, Postmenopausal · United States, Australia, Belgium and more | 4 | Completed | Jan 7, 2015 | 643 |
| NCT01575873Steroid-induced Osteopor, Glucocorticoid-induced Ostepor · United States, Argentina, Belgium and more | 3 | Completed | Jun 21, 2016 | 795 |
| NCT01464931Renal Insufficiency · United States | 1 | Completed | Jan 2013 | 32 |
| NCT01419717Neoplasms · Argentina, Austria, Belgium and more | 3 | Completed | Aug 10, 2018 | 129 |
| NCT01345019Neoplasms · United States, Australia, Austria and more | 3 | Completed | Jul 19, 2016 | 1,718 |
| NCT01294397Bone Diseases, Metabolic · United States | 1 | Terminated | Jan 2016 | 19 |
| NCT01221727Osteoporosis, Postmenopausal | 1 | Completed | Jul 2011 | 30 |
| NCT01077154Breast Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Aug 31, 2017 | 4,509 |
| NCT00980174Bone Diseases, Metabolic | 3 | Completed | Jun 21, 2011 | 242 |
| NCT00950911Multiple Myeloma · Czech Republic, United Kingdom | 3 | Completed | Feb 2012 | 35 |
| NCT00936897Osteoporosis, Postmenopausal | 3 | Completed | Nov 2011 | 833 |
| NCT00925600Neoplasms · United States, Australia, Bulgaria and more | 3 | Completed | May 12, 2016 | 769 |
| NCT00919711Osteoporosis | 3 | Completed | Dec 21, 2011 | 870 |
| NCT00896532Bone Diseases, Metabolic | 2 | Completed | Feb 21, 2011 | 419 |
| NCT00896454Breast Neoplasms · United States, Canada, France and more | 2 | Completed | Sep 13, 2012 | 33 |
| NCT00890981Bone Diseases, Metabolic | 3 | Completed | Jun 2010 | 79 |
| NCT00838201Neoplasms · United States, Canada, Finland and more | 3 | Completed | May 3, 2012 | 384 |
| NCT00680992Neoplasms · United States, Australia, Austria and more | 2 | Completed | May 17, 2018 | 535 |
| NCT00556374Breast Neoplasms · Austria, Sweden | 3 | Completed | Oct 7, 2014 | 3,420 |
| NCT00523341Bone Diseases, Metabolic | 3 | Completed | Jul 19, 2015 | 4,550 |
| NCT00518531Osteoporosis | 3 | Completed | Jun 1, 2009 | 250 |
| NCT00515463Bone Diseases, Metabolic | 3 | Completed | Mar 2008 | 311 |
| NCT00396279Giant Cell Tumor of Bone | 2 | Completed | Apr 7, 2008 | 37 |
| NCT00377819Osteoporosis, Postmenopausal | 3 | Completed | Mar 2008 | 504 |
| NCT00330759Multiple Myeloma | 3 | Completed | Apr 1, 2009 | 1,779 |
| NCT00325468Bone Diseases, Metabolic | 3 | Completed | Mar 28, 2011 | 200 |
| NCT00321620Fractures, Bone | 3 | Completed | Oct 1, 2009 | 1,904 |
| NCT00321464Fractures, Bone | 3 | Completed | Jul 20, 2009 | 2,049 |
| NCT00330460Osteoporosis | 3 | Completed | Nov 2007 | 1,189 |
| NCT00306189Osteoporosis | 2 | Completed | Jun 2007 | 212 |
| NCT00293813Osteoporosis, Postmenopausal | 2 | Completed | Mar 2008 | 247 |
| NCT00286091Hormone Refractory Prostate Cancer | 3 | Completed | Jul 30, 2010 | 1,435 |
| NCT00259740Recurrence | 2 | Completed | Aug 2007 | 96 |
| NCT00095498Arthritis, Rheumatoid | 2 | Completed | Apr 1, 2007 | 227 |
| NCT00091832Breast Neoplasms | 2 | Completed | Nov 2005 | 255 |
| NCT00091793Osteoporosis, Postmenopausal | 3 | Completed | Feb 2009 | 332 |
| NCT00089791Osteoporosis | 3 | Completed | Jun 17, 2008 | 7,808 |
| NCT00089674Prostatic Neoplasms | 3 | Completed | May 16, 2008 | 1,468 |
| NCT00089661Breast Neoplasms | 3 | Completed | May 11, 2007 | 252 |
| NCT00043186Bone Diseases, Metabolic | 2 | Completed | Apr 2007 | 412 |
How it is read
Names in the registry
- “Denosumab”, 41 entries
- “denosumab”, 10 entries
- “CT-P41”, 3 entries
- “AMG 162”, 3 entries
- “Prolia®”, 2 entries
Codes read as this program: CMAB807.
Conditions, from the studies’ own filings
- Osteoporosis, Postmenopausal, 21 studies
- Osteoporosis, 16 studies
- Breast Neoplasms, 5 studies
- Giant Cell Tumor of Bone, 4 studies
- Prostatic Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.